INTELLIGENT BIO SOLUTIONS INC. Business Acquisition, Pro Forma Net Income (Loss)
INTELLIGENT BIO SOLUTIONS INC. (INBS) reported Business Acquisition, Pro Forma Net Income (Loss) of -$10.63 million for the 12-month period ending 2023-06-30, per its 10-K filed 2024-09-18.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2024-09-18
- INTELLIGENT BIO SOLUTIONS INC. business acquisition, pro forma net income (loss) for the quarter ending 2023-06-30 was -$2.66M.
- INTELLIGENT BIO SOLUTIONS INC. business acquisition, pro forma net income (loss) for the quarter ending 2023-03-31 was -$6.34M.
- INTELLIGENT BIO SOLUTIONS INC. business acquisition, pro forma net income (loss) for the quarter ending 2022-12-31 was -$420.60K.
- INTELLIGENT BIO SOLUTIONS INC. business acquisition, pro forma net income (loss) for the quarter ending 2022-09-30 was -$1.21M.
- INTELLIGENT BIO SOLUTIONS INC. business acquisition, pro forma net income (loss) for fiscal 2023 was -$10.63M.
- INTELLIGENT BIO SOLUTIONS INC. business acquisition, pro forma net income (loss) for fiscal 2022 was -$8.31M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|
| 2023-06-30 | -$2.66M derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-18 | -$9.00M derived: sum of 2 quarters · filed 2024-09-18 | -$9.42M derived: sum of 3 quarters · filed 2024-09-18 | -$10.63M 10-K · filed 2024-09-18 |
| 2023-03-31 | -$6.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-08 | -$6.76M derived: sum of 2 quarters · filed 2024-05-08 | -$7.97M 10-Q · filed 2024-05-08 | -$10.05M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$420.60K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-09 | -$1.63M 10-Q · filed 2024-02-09 | -$3.71M derived: sum of 3 quarters · filed 2024-02-09 | -$5.04M derived: sum of 4 quarters · filed 2024-02-09 |
| 2022-09-30 | -$1.21M 10-Q · filed 2023-11-08 | -$3.29M derived: sum of 2 quarters · filed 2023-11-08 | -$4.62M derived: sum of 3 quarters · filed 2023-11-08 | |
| 2022-06-30 | -$2.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-08-23 | -$3.41M derived: sum of 2 quarters · filed 2023-08-23 | -$8.31M 10-K · filed 2023-08-23 | |
| 2022-03-31 | -$1.34M 10-Q · filed 2023-05-11 | -$6.23M 10-Q · filed 2023-05-11 | ||
| 2021-06-30 | -$7.04M 10-Q · filed 2023-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| enVVeno Medical Corp (NVNO) | United States | $0.006B | -0.48 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Co-Diagnostics, Inc. (CODX) | United States | $0.007B | -0.32 |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |